Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|November 1, 2004

Supplements and Featured Publications

  • Decision Maker News in Managed Care - Proceedings from the 2004 Cambridge Healthcare Summit, Part II
  • Volume 10
  • Issue 3 Decision

Editorial Advisory Board

David A. Asch, MD, MBA

Executive Director

Leonard Davis Institute of Health Economics

Philadelphia, Pennsylvania

Eric Cannon, PharmD

Director

Pharmacy Services & Health and Wellness

IHC Health Plans

Salt Lake City, Utah

Jeffrey Casberg, MS, RPh

Director of Pharmacy

ConnectiCare

Farmington, Connecticut

Martin Grubin, MD

Medical and Pharmacy Director

Central Health

Covina, California

Neil Minkoff, MD

Medical Director

Harvard Pilgrim Health Care

Wellesley, Massachusetts

Lawrence Mullany, MD

Medical Director

AvMed Health Plans

Gainesville, Florida

Burton I. Orland, RPh, BS

Vice President of Pharmacy

Oxford Health Plans

Trumbull, Connecticut

L. Gregory Pawlson, MD, MPH

Executive Vice President

NCQA

Washington, DC

John R. Rodgers, RPh, MBA

Director of Pharmacy

Independent Health

Buffalo, New York

Mark Rubino, RPh, MHA

Chief Pharmacy Officer

Aetna

Blue Bell, Pennsylvania

Steven Wolinsky, MD

Senior Medical Director

Policy and Pharmacy

Empire BCBS

New York, New York

Articles in this issue

almost 22 years ago

Pay for Performance: Two Critical Steps Needed to Achieve a Successful Program

almost 22 years ago

Hot Topics

almost 22 years ago

CME/CE Quiz

almost 22 years ago

Employer Direction in Healthcare Coverage: Growing Dissatisfaction Leads to New Strategies

Related to this article

View more
Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Read more
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel. | Image: LinkedIn
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Read more